Amgen Inc. (AMGN)

226.72
1.20 0.54
NASDAQ : Health Technology
Prev Close 225.51
Open 227.12
Day Low/High 225.02 / 227.56
52 Wk Low/High 166.30 / 226.55
Volume 156.60K
Avg Volume 2.48M
Exchange NASDAQ
Shares Outstanding 594.18M
Market Cap 133.39B
EPS 12.70
P/E Ratio 17.24
Div & Yield 5.80 (2.57%)

Latest News

Amgen Announces New FOURIER Analysis Showing Benefit Of Repatha® (evolocumab) In High-Risk Patients Who Have Experienced A Recent Heart Attack

Amgen Announces New FOURIER Analysis Showing Benefit Of Repatha® (evolocumab) In High-Risk Patients Who Have Experienced A Recent Heart Attack

Additional FOURIER Analysis Shows Lowering LDL-C With Repatha Did Not Impair Patient-Reported Cognition

Amgen And The Duke Clinical Research Institute Announce Initiation Of First Large-Scale Registry To Evaluate Real-World Lipid Management And The Effectiveness Of PCSK9 Inhibitors

Amgen And The Duke Clinical Research Institute Announce Initiation Of First Large-Scale Registry To Evaluate Real-World Lipid Management And The Effectiveness Of PCSK9 Inhibitors

New Registry, cvMOBIUS, Will Assess Lipid Therapies and Five-Year Cardiovascular Outcomes in 8,500 High-Risk Patients With a Recent Atherosclerotic Cardiovascular Disease Event

See How Amgen Ranks Among Analysts' Top Picks With Strong Buyback Activity

See How Amgen Ranks Among Analysts' Top Picks With Strong Buyback Activity

A study of analyst recommendations at the major brokerages shows that Amgen Inc is the #71 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity. To make that list, a stock must have repurchased at least 5% of its outstanding shares over the trailing twelve month period.

Amgen at 52-Week Highs Bumps Against Resistance, Remains a Long-Term Hold

Amgen at 52-Week Highs Bumps Against Resistance, Remains a Long-Term Hold

Shares of biopharma giant Amgen have rallied more than 30% since their summer lows and recently hit all-time highs. Investors should now be cautious in the short term due to a strong fundamental resistance level.

Amgen Highlights Data To Be Presented At AHA 2019 Across Cardiovascular Portfolio

Amgen Highlights Data To Be Presented At AHA 2019 Across Cardiovascular Portfolio

New Analyses From the Landmark Repatha® (Evolocumab) FOURIER Cardiovascular Outcomes Study Evaluate Clinical Efficacy and Outcomes in Diverse High-Risk Patient Populations

Amgen To Present At The 28th Annual Credit Suisse Healthcare Conference

Amgen To Present At The 28th Annual Credit Suisse Healthcare Conference

THOUSAND OAKS, Calif., Nov.

Adding to AbbVie

We feel we are finally getting our chance to get bigger in this still very much beaten down and inexpensive biopharmaceutical stock.

Real Money Post Industrial Average Exits October on Top

Real Money Post Industrial Average Exits October on Top

The RMPIA's 3.8% jump even beat the Nasdaq Composite Index's 3.7% October climb.

Drug Companies Are a Political Football, Trading Amgen: Market Recon

Drug Companies Are a Political Football, Trading Amgen: Market Recon

The nation enters an electoral season. The drug companies for the most part, have no friends on either side of the aisle.

Jobs Report, Exxon, Pinterest, Amgen, U.S. Steel - 5 Things You Must Know Friday

Jobs Report, Exxon, Pinterest, Amgen, U.S. Steel - 5 Things You Must Know Friday

U.S. stock futures rise ahead of a U.S. jobs report that is expected to show a notable slowdown in U.S. job creation in October; Exxon Mobil, Chevron, Alibaba and AbbVie report earnings; Pinterest shares fall sharply after the company misses third-quarter revenue estimates.

Celgene Slips on Post-Earnings Analyst Downgrade

Celgene Slips on Post-Earnings Analyst Downgrade

Shares of pharmaceutical giant Celgene slip after receiving a downgrade from analysts at Baird, despite posting better-than-expected quarterly results.

Amgen Takes $2.7 Billion Stake in BeiGene to Expand Access to China

Amgen Takes $2.7 Billion Stake in BeiGene to Expand Access to China

Shares of biotech firm rocket in after-hours trading.

Amgen Enters Into Strategic Collaboration With BeiGene To Expand Oncology Presence In China

Amgen Enters Into Strategic Collaboration With BeiGene To Expand Oncology Presence In China

Amgen to Acquire 20.5% Stake in BeiGene for Approximately $2.7 Billion in Cash

We Prescribe Amgen to Treat Your Portfolio

We Prescribe Amgen to Treat Your Portfolio

According to the charts, the drugmaker should break out to new highs.

Forget About the Fed: Cramer's 'Mad Money' Recap (Wednesday 10/30/19)

Forget About the Fed: Cramer's 'Mad Money' Recap (Wednesday 10/30/19)

Jim Cramer says not having enough time, and having too much government regulation, have more impact on the future revenue streams of companies than does the Federal Reserve.

The Discovery Of Amgen's Novel Investigational KRAS(G12C) Inhibitor AMG 510 Published In Nature

The Discovery Of Amgen's Novel Investigational KRAS(G12C) Inhibitor AMG 510 Published In Nature

Publication Showcases how First-to-Clinic Investigational AMG 510 Exploits a Cryptic Groove of the Previously Undruggable KRAS Protein Surface

Jim Cramer: Drug Stocks Are Too Cheap

Jim Cramer: Drug Stocks Are Too Cheap

These stocks are priced for total imperfection. That's just what you want.

Sussing the Fed -- Plus Apple, Amgen and Other Earnings: Market Recon

Sussing the Fed -- Plus Apple, Amgen and Other Earnings: Market Recon

Markets are watching what Fed Chair Powell will signal for future rate cuts during this afternoon's FOMC rate decision.

Amgen Reports Third Quarter 2019 Financial Results

Amgen Reports Third Quarter 2019 Financial Results

THOUSAND OAKS, Calif., Oct.

6 Market Winds of Change, Trading Beyond Meat, GrubHub Earnings: Market Recon

6 Market Winds of Change, Trading Beyond Meat, GrubHub Earnings: Market Recon

If there was not a sizable addressable market for Beyond Meat, the competition would not be building as quickly as it is.

Jim Cramer: Demand Is Driving This Market to All-Time Highs

Jim Cramer: Demand Is Driving This Market to All-Time Highs

The stocks of many companies anticipated a more stringent series of tariffs and we didn't get them.

Amgen Announces Webcast Of 2019 Third Quarter Financial Results

Amgen Announces Webcast Of 2019 Third Quarter Financial Results

THOUSAND OAKS, Calif., Oct.

Amgen To Make Repatha® (evolocumab) Available Exclusively At Its Lower List Price Option In 2020

Amgen To Make Repatha® (evolocumab) Available Exclusively At Its Lower List Price Option In 2020

Repatha Original List Price Option Will be Discontinued Effective Dec. 31, 2019

Amgen Recommends Rejection Of 'Mini-Tender' Offer From TRC Capital Corporation

Amgen Recommends Rejection Of 'Mini-Tender' Offer From TRC Capital Corporation

THOUSAND OAKS, Calif., Oct.

David Meline, Amgen's Chief Financial Officer, To Retire

David Meline, Amgen's Chief Financial Officer, To Retire

Peter Griffith to Assume CFO Role in 2020

Amgen Announces 2019 Fourth Quarter Dividend

Amgen Announces 2019 Fourth Quarter Dividend

THOUSAND OAKS, Calif., Oct.

Arrowhead Pharmaceuticals Is Flying Higher on the Charts

Arrowhead Pharmaceuticals Is Flying Higher on the Charts

Before I give my recommendation I want to visit with the charts and indicators.

TheStreet Quant Rating: A- (Buy)